Pulse Biosciences Reports $0.4M Q1 Revenue, $18.6M Loss on Increased Clinical Investment
PLSE sits 64% above its 52-week low of $12.56.
Summary
Pulse Biosciences reported Q1 revenue of $0.4 million, reflecting early-stage product sales, while its GAAP net loss widened to $18.6 million. The increased loss was primarily driven by higher investment in clinical programs, a strategic move following the highly positive 12-month clinical data for its nPulse Cardiac Catheter System announced in late April. For a clinical-stage biotech, this investment is critical for advancing its pipeline towards commercialization, despite impacting short-term profitability. Investors will be watching for the completion of enrollment for the NANOPULSE-AF pivotal trial in early Q4 2026, the NANOCLAMP-AF surgical AF ablation trial by mid-2027, and the papillary thyroid microcarcinoma study by year-end 2026.
At the time of this announcement, PLSE was trading at $20.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $12.56 to $26.30. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.